Lamellar macular hole after intravitreal ocriplasmin injection

Ross Bronson Chod, Clifford Goodrich, Sandeep Saxena, Levent Akduman

Research output: Contribution to journalArticlepeer-review

6 Scopus citations


Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.

Original languageEnglish (US)
Article number207810
JournalBMJ Case Reports
StatePublished - Jan 9 2015
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Lamellar macular hole after intravitreal ocriplasmin injection'. Together they form a unique fingerprint.

Cite this